Company intelligence / Profile preview

Amplifi Vascular

Chesterfield, Missouri, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

In a first-in-human study of end-stage kidney disease patients, the Amplifi Vein Dilation System increased cephalic vein diameter by 151% and flow rate by 134% on average, with AVFs maturing within two weeks and all patients cleared for dialysis by week six. No serious device-related or procedural adverse events observed. Device is under development; larger pivotal trials are planned.

Therapeutic areas: NephrologyCardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Amplifi Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amplifi Vascular.

Explore the full profile